Electronic Nose Device Intrigues Cannabis Investor Community


NEW YORK (MainStreet) — What started as an Indiegogo campaign to determine market demand for a sensor device that will test the chemical composition of cannabis is now a full fledged start-up called Cdx that garnered the interest of serious investors at the ArcView Investor Network in Boston last week with its MyDx Analyzer for Cannabis.

Also See: Inside the Legal Pot Industry's Most Illustrious Investor Network

"Right now people have no idea what they are smoking," said Daniel Yazbeck, a lead investor backing MyDx, which is registered in Delaware and headquartered in San Diego. "They hope it will make them feel better but if you want true quality control you have to know what you are putting into your body."

Also See: Zynga Co-Founder Launches Cannabis Cooling System

The handheld MyDx for Cannabis device retails for $399 compared to $499 for the multi-use gadget, which average consumers can use to screen out pesticides while shopping for vegetables at a farmer's market or grocery store.

"MyDx will test for THC and CBD and pesticides in the gas phase," Yazbeck said. "It's an electronic nose. With 400 different chemicals in cannabis, the ratio of these chemicals is what's important because the ratio will alter the feeling you will have."

Not only is MyDx tiny enough to fit in a purse or coat pocket but it is also Bluetooth-equipped for cell phones so that once the MyDx app is downloaded, results from a swipe of spinach or cannabis leaf inserted into the sample chamber instantly appear on the screen of a mobile device so the data can be tracked by the user.

"The end consumer will be more in control using MyDx," said Troy Dayton, CEO of the ArcView Group Investor Network in Boston last week. "It's practical and for a smaller dispensary who can't afford a $5,000 machine, MyDx makes it easier to know what you're getting from the grower. It will give them a good, relative measure quickly."

Also See: Cannabis Companies: At ArcView, Investors Pay to Play


Investors at the ArcView conference were largely enthusiastic about the concept behind the MyDx device.

Summit Trading's Charles Arnold said MyDx was on his list of interesting start-ups to explore along with a company that manufactures the components of cannabinoids in capsule form.

"My interest until there's federal approval is to stay away from the cultivation of marijuana and concentrate on ancillary companies and then the ongoing medical potential of processing these products through cannabinoids," said Arnold, who is invested in Surna, a company that develops climate cooling systems for pot dispensaries and growing facilities.

Currently, Yazbeck is helping CDx complete its series A financing to help grow the company and deliver on the MyDx pre-orders they are receiving.

"A family fund from the oil and gas industry just wired money to our law firm who is managing the current financing round," Yazbeck said. "Investors are looking to cannabis for a return on their investment and MyDx gives them access to cannabis, food, water and air quality markets."

If MyDx doesn't go public or get acquired, CDx plans a round of series B financing.

"Our manufacturing costs are high because of the design and components in MyDx and the sensor," said Yazbeck. "Our engineers are going through the final re-design for manufacturing efforts at this time so we can deliver product by Christmas of this year."

--Written by Juliette Fairley for MainStreet

Show Comments

Back to Top